Human antibody profiling technologies for autoimmune disease

Abstract

Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilised to discover and map novel autoantigens associated with disease. This review compares human autoantigen profiling technologies including the application of these approaches in chronic and post-infectious autoimmune disease. Each technology has advantages and limitations that should be considered when designing new projects to profile autoantibodies. Recent studies that have utilised these technologies across a range of diseases have highlighted marked heterogeneity in autoantibody specificity between individuals as a frequent feature. This individual heterogeneity suggests that epitope spreading maybe an important mechanism in the pathogenesis of autoimmune disease in general and likely contributes to inflammatory tissue damage and symptoms. Studies focused on identifying autoantibody biomarkers for diagnosis should use targeted data analysis to identify the rarer public epitopes and antigens, common between individuals. Thus, utilisation of human autoantigen profiling technology, combined with different analysis approaches, can illuminate both pathogenesis and biomarker discovery.

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

“… 5 In addition, some studies reported heterogeneity among individuals in the autoantibody binding sites and their effect. 28 , 29 The role of EPO-EPOR in the pathophysiology of anemia may differ by ethnicity. Because the proportion of participants from Japan was small in the CREDENCE trial, this may explain potential differences with earlier studies, which were exclusively performed in Japanese participants.…”

Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects

“…Следует подчеркнуть инновационные «аутоантигеномные» методы, которые в последние годы все шире используются для определения аутоантител при САРЗ и COVID-19, позволяющие выявлять аутоантитела к ранее не известным аутоантигенам, и при заболеваниях, которые ранее не рассматривались как аутоиммунные, имеют методические ограничения (характер гликозилирования аутоантител и пост трансляционной модификации аутоантигенов и др.) [312] и нуждаются в стандартизации и валидации [313][314][315]. Дос тупные для клинической практики методы, позволяющие дифференцировать «патогенные» от «защитных» аутоантител, охарактеризовать их субкласс, аллотип, гликозилирование [316,317] и, что самое важное, их функциональную активность, не разработаны.…”

Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)

“…Advanced high-profile techniques, such as solid surface arrays and display technologies,16 have been boosting the biomarker discovery. Despite considerable progress and widespread application in autoantibody discovery,17–19 the utility of high-throughput assays, particularly protein microarrays, remains restricted by the limited amount of miniaturised test sites.…”